CA2043440A1 - Methode de traitement de l'impuissance - Google Patents

Methode de traitement de l'impuissance

Info

Publication number
CA2043440A1
CA2043440A1 CA2043440A CA2043440A CA2043440A1 CA 2043440 A1 CA2043440 A1 CA 2043440A1 CA 2043440 A CA2043440 A CA 2043440A CA 2043440 A CA2043440 A CA 2043440A CA 2043440 A1 CA2043440 A1 CA 2043440A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
treating impotence
erectile impotence
impotence
reliev
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2043440A
Other languages
English (en)
Other versions
CA2043440C (fr
Inventor
George Mclean Milne
Michael Grant Wyllie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2043440A1 publication Critical patent/CA2043440A1/fr
Application granted granted Critical
Publication of CA2043440C publication Critical patent/CA2043440C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Harvester Elements (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Tone Control, Compression And Expansion, Limiting Amplitude (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
CA002043440A 1990-05-31 1991-05-29 Methode de traitement de l'impuissance Expired - Fee Related CA2043440C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53149490A 1990-05-31 1990-05-31
US07/531,494 1990-05-31

Publications (2)

Publication Number Publication Date
CA2043440A1 true CA2043440A1 (fr) 1991-12-01
CA2043440C CA2043440C (fr) 1996-07-30

Family

ID=24117862

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002043440A Expired - Fee Related CA2043440C (fr) 1990-05-31 1991-05-29 Methode de traitement de l'impuissance

Country Status (15)

Country Link
EP (1) EP0459666B1 (fr)
JP (1) JP2522609B2 (fr)
KR (1) KR930010582B1 (fr)
AT (1) ATE113839T1 (fr)
AU (1) AU620282B2 (fr)
CA (1) CA2043440C (fr)
DE (1) DE69105040T2 (fr)
DK (1) DK0459666T3 (fr)
HU (1) HU208076B (fr)
IE (1) IE63837B1 (fr)
IL (1) IL98258A (fr)
MY (1) MY106528A (fr)
NZ (1) NZ238339A (fr)
PT (1) PT97785B (fr)
ZA (1) ZA914135B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4223800A1 (de) * 1992-07-20 1994-01-27 Cassella Farbwerke Mainkur Ag Verwendung von 1.2.5-Oxadiazol-2-oxiden zur Behandlung erektiler Dysfunktionen
DE69423533T2 (de) * 1993-02-10 2000-08-24 B.M.R.A. Corp. B.V., Rotterdam Zubereitungen zur Behandlung von Impotenz, die ein Alpha-1 inhibitor und ein Alpha-2 inhibitor enthalten
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
EE9700209A (et) * 1994-11-16 1998-04-15 Synaptic Pharmaceutical Corporation Dihüdropürimidiinid ja nende kasutamine
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
KR19980703052A (ko) * 1995-03-14 1998-09-05 윌리엄 엘. 스미스 발기 기능장애의 예방 방법 및 키트
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
YU49898A (sh) 1996-05-10 2000-03-21 Icos Corporation Hemijska jedinjenja
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
EP0849265A1 (fr) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Nouvelle forme polymorphique de mésylate de doxazosin (forme II)
EP0849264A1 (fr) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Nouvelle forme polymorphique de mésylate de doxazosin (forme I)
PT849266E (pt) * 1996-12-20 2007-03-30 Heumann Pcs Gmbh Nova forma polimorfa de mesilato de doxazosina (forma iii)
HUP0100705A3 (en) * 1997-12-16 2001-12-28 Pfizer Prod Inc Combination effective for the treatment of impotence
DE19800214A1 (de) 1998-01-06 1999-07-15 Knoll Ag Verfahren zur Herstellung von Doxazosin-Mcsylat in einer als Form A bezeichneten Kristallmodifikation und ein Zwischenprodukt dafür
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
RU2135195C1 (ru) * 1998-12-17 1999-08-27 Овсюк Валерий Григорьевич Способ получения материала, содержащего клетки предстательной железы, материал, содержащий клетки предстательной железы, и способы лечения фиброматоза матки, хронического простатита и нарушений мужской половой функции методом трансплантации
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
DE60126265T2 (de) * 2000-05-12 2007-10-31 Novalar Pharmaceuticals, Inc. Zusammensetzung bestehend aus Phentolaminmesylat und deren Verwendung
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925837A (en) * 1984-09-14 1990-05-15 Synthelabo Pharmaceutical compositions

Also Published As

Publication number Publication date
ZA914135B (en) 1993-01-27
EP0459666B1 (fr) 1994-11-09
IE911842A1 (en) 1991-12-04
HUT58520A (en) 1992-03-30
DE69105040T2 (de) 1995-03-23
HU911810D0 (en) 1991-12-30
JPH04235917A (ja) 1992-08-25
DK0459666T3 (da) 1994-12-05
AU620282B2 (en) 1992-02-13
MY106528A (en) 1995-06-30
AU7807791A (en) 1991-12-05
CA2043440C (fr) 1996-07-30
HU208076B (en) 1993-08-30
IE63837B1 (en) 1995-06-14
IL98258A0 (en) 1992-06-21
NZ238339A (en) 1997-07-27
PT97785B (pt) 1999-01-29
ATE113839T1 (de) 1994-11-15
IL98258A (en) 1996-01-31
EP0459666A2 (fr) 1991-12-04
DE69105040D1 (de) 1994-12-15
JP2522609B2 (ja) 1996-08-07
PT97785A (pt) 1992-02-28
EP0459666A3 (en) 1992-06-03
KR930010582B1 (ko) 1993-10-30
KR910019618A (ko) 1991-12-19

Similar Documents

Publication Publication Date Title
CA2043440A1 (fr) Methode de traitement de l'impuissance
CA2263561A1 (fr) Thienopyrimidines
EP0509019A4 (en) Treatment of human retroviral infections with 2',3'-dideoxyinosine
CA2186260A1 (fr) Composition contenant de la morphine, du polypyrrolidone et un polyalyleneoxyde
CA2211802A1 (fr) Composition pharmaceutique pour le traitement de l'herpes
WO1996028185A3 (fr) Composition contenant de l'amlopidine, ou un sel ou de la felodipine et un inhibiteur de l'enzyme de conversion de l'angiotensine
GEP19971030B (en) Method for preparation of derivatives of 1-benzil-3-oximetil-indazolului or salts with pharmaceutically acceptable bases
CA2179733A1 (fr) Sulfamates de pseudofructopyranose anticonvulsifs
HK217196A (en) Diamine salts of clavulanic acid
HUT48623A (en) Herbicides comprising 2,5-dihydropyrrole derivatives as active ingredient and process for producing 2,5-dihydropyrrole derivatives
EP0675953A4 (fr) Peptides solubles possedant une conformation secondaire contrainte en solution et procede de preparation de ces composes.
AU620218B2 (en) Anti-hiv drug
EP0362847A3 (fr) Emploi de l'étopéritone pour obtenir une composition pharmaceutique pour le traitement de l'impotence chez l'homme
NZ230356A (en) 2',3'-dideoxy-5-ethynyl-3'-fluorouridine: preparatory processes and pharmaceutical compositions
CA2114859A1 (fr) Compose cytotoxique et antiviral
CA2158354A1 (fr) Utilisation de granisetron pour le traitement de nausees et de vomissements postoperatoires
CA2018461A1 (fr) Polypeptides et leur utilisation
AU589148B2 (en) Medicament for the treatment of acquired immune deficiency syndrome and corresponding pharmaceutical compositions and method of treatment
EP0357072A3 (fr) Utilisation de zofénopril pour la préparation de médicaments contre l'arthrite rhumatismale
AU672791B2 (en) N-derivatives of (phenylethyl-beta-ol) amine, a process for their preparation and pharmaceutical compositions containing the same
CA2101548A1 (fr) Acides acylamino-alylidenehydroxy-bisphosphoniques, utiles pour le traitement des maladies osteoarticulaires
EP0509098A4 (en) Ataractic
HUT47081A (en) Process for producing pharmaceutical compositions against endogeneous parasites and a group of the active components, namely the new n-substituted oxy-carbonyl-esters
NZ240927A (en) Dibenz-oxa-thiocinones; preparatory processes, uses, and pharmaceutical compositions
CS180391A3 (en) Preventive, tonic and anti-sclerotic composition and process for preparingan active component thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed